 | • レポートコード：B-MOR-08274 • 出版社/出版日：Mordor Intelligence / 2018年5月15日 • レポート形態：英文、PDF、107ページ • 納品方法：Eメール（受注後2営業日） • 産業分類：Healthcare |
| Single User（1名様用） | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User（7名様用） | ￥666,000 (USD4,500) | ▷ お問い合わせ |
| Corporate User | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、インフルエンザ診断の世界市場について調べ、インフルエンザ診断の世界規模、市場動向、市場環境、テストタイプ別（従来型診断テスト、分子診断アッセイ）分析、エンドユーザー別（病院、研究所、その他）分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、企業の競争環境、関連企業情報などをまとめた調査レポートです。 ・イントロダクション ・エグゼクティブサマリー ・インフルエンザ診断の世界市場インサイト ・インフルエンザ診断の世界市場環境 ・インフルエンザ診断の世界市場動向 ・インフルエンザ診断の世界市場規模 ・インフルエンザ診断の世界市場規模：テストタイプ別（従来型診断テスト、分子診断アッセイ） ・インフルエンザ診断の世界市場規模：エンドユーザー別（病院、研究所、その他） ・インフルエンザ診断の世界市場：地域別市場規模・分析 ・インフルエンザ診断の北米市場規模・予測 ・インフルエンザ診断のアメリカ市場規模・予測 ・インフルエンザ診断のヨーロッパ市場規模・予測 ・インフルエンザ診断のアジア市場規模・予測 ・インフルエンザ診断の日本市場規模・予測 ・インフルエンザ診断の中国市場規模・予測 ・インフルエンザ診断のインド市場規模・予測 ・インフルエンザ診断の韓国市場規模・予測 ・関連企業情報・競争状況 |
The influenza diagnostics market is expected to register a growth rate of nearly 8.0% during the forecast period, 2018 to 2023. The market for the infectious disease of the upper respiratory system caused by the influenza virus is expected to register steady growth driven by rising prevalence of influenza diseases and associated chronic diseases with the rise in technological advancements in the influenza diagnosis. The rising awareness of early diagnosis and well-developed healthcare infrastructure and higher adoption of advanced diagnostic technologies helps North America to dominate the share in this market.
Growing Prevalence of Influenza and Associated Chronic Diseases
The growing prevalence of influenza and associated chronic diseases primarily drives the influenza diagnostics market. According to World Health Organization (WHO), the annual epidemics are estimated to be around 3 to 5 million cases of severe illness and about 0.20-0.65 million respiratory-related deaths. In the industrialized countries influenza is primarily associated with the older population above 65-year-old and in developing countries, it is majorly infected in children below 5-year-old lower respiratory tract infections. In several studies, it has been found that Rapid Influenza Diagnostic Tests (RIDT) is considered to be one of the most effective assays with better performance among children as compared to adults. Thus, increasing prevalence plays a major role in increasing demand of influenza diagnostics.
Other factors driving this market are growth in research funding for new better influenza diagnostics, rising demand for early diagnostics and control of influenza and emergence of technologically advanced influenza diagnostic tests.
Variability in Sensitivity and Specificity Among Influenza Diagnostic Tests
The variability in sensitivity and specificity among the influenza diagnostic tests is among the primary reasons restricting the growth of this market. In most rapid flu tests, there are difficulties in reliably identifying the patients with influenza. The sensitivity ranges are highly variable between 10-90% across various patient populations. With that, as the influenza season at its peak, most diagnostic tests show an increase in the rate of false negative results, which often leads to misdiagnosing. Thus, this hinders the growth of this market.
Other factors limiting the growth of this market are product safety and the high cost of development with stringent government regulations.
Asia Pacific to Witness the Fastest Growth Rate
Asia Pacific is expected to dominate the fastest growth rate in the forecast period. The healthy CAGR is expected due to rising healthcare expenditure in countries, such as India, China, and Japan. This is accompanied by increasing affordability and subsidized immunization for elderly in Australia, Japan, and South Korea. The developing countries have increased incidence of seasonal influenza particularly in South Asian countries often linked to increasing geriatric population, changing dietary habits, and high consumption preserved food.
Key Developments in the Market
• March, 2018 – Sekisui Diagnostics launched the Silaris Influenza A and B test developed in collaboration with Mesa Biotech.
Major players: 3M, ABBOTT, BECTON, DICKINSON AND COMPANY, DIASORIN S.P.A., F. HOFFMANN-LA ROCHE AG, LUMINEX CORPORATION, MERIDIAN BIOSCIENCE, INC, QUIDEL CORPORATION, SEKISUI DIAGNOSTICS, AND THERMO FISHER SCIENTIFIC INC, amongst others.
Reasons to Purchase this Report
• Current and future of influenza diagnostics market outlook in the developed and emerging markets
• Analysis of various perspectives of the market with the help of Porter’s five forces analysis
• The segment that is expected to dominate the market
• Regions that are expected to witness the fastest growth during the forecast period
• Identify the latest developments, market shares, and strategies employed by the major market players
• 3- months analyst support, along with the Market Estimate sheet (in excel)
Customization of the Report
• This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs
レポート目次1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter’s Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry within the Industry
6. Market Dynamics
6.1 Market Drivers
6.1.1 Increasing Prevalence of Influenza and Related Chronic Diseases
6.1.2 Growth in Research Funding for Influenza Diagnostics
6.1.3 Rising Demand for Early Diagnosis and Control of Influenza
6.1.4 Emergence of Technologically Advanced Influenza Diagnostic Tests
6.2 Market Restraints
6.2.1 Product Safety and High Cost of Development
6.2.2 Stringent Government Regulations
6.2.3 Variability in Sensitivity and Specificity Among Influenza Diagnostic Tests
6.3 Opportunities
6.4 Key Challenges
7. Market Segmentation
7.1 By Test Type
7.1.1 Traditional Diagnostic Tests
7.1.1.1 Rapid Influenza Diagnostic Tests (RIDT)
7.1.1.2 Viral Culture
7.1.1.3 Direct Fluorescent Antibody (DFA) Tests
7.1.1.4 Serological Assays
7.1.2 Molecular Diagnotic Assays
7.1.2.1 RT-PCR
7.1.2.2 Nucleic Acid Sequence-Based Amplification (NASBA) Tests
7.1.2.3 Loop-Mediated Isothermal Amplification-Based Assays (LAMP)
7.1.2.4 Simple Amplification-Based Assays (SAMBA)
7.1.2.5 Other Molecular Diagnostic Tests
7.2 By End-user
7.2.1 Hospitals
7.2.2 Research Laboratories
7.2.3 Others
7.3 By Geography
7.3.1 North America
7.3.1.1 US
7.3.1.2 Canada
7.3.1.3 Mexico
7.3.2 Europe
7.3.2.1 France
7.3.2.2 Germany
7.3.2.3 UK
7.3.2.4 Italy
7.3.2.5 Spain
7.3.2.6 Rest of Europe
7.3.3 Asia-Pacific
7.3.3.1 China
7.3.3.2 Japan
7.3.3.3 India
7.3.3.4 Australia
7.3.3.5 South Korea
7.3.3.6 Rest of Asia-Pacific
7.3.4 Middle East & Africa
7.3.4.1 GCC
7.3.4.2 South Africa
7.3.4.3 Rest of MEA
7.3.5 South America
7.3.5.1 Brazil
7.3.5.2 Argentina
7.3.5.3 Rest of South America
8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches
9. Key Players
9.1 3M
9.2 Abbott
9.3 Becton, Dickinson and Company
9.4 DiaSorin s.p.a.
9.5 F. Hoffmann-La Roche AG
9.6 Luminex Corporation
9.7 Meridian Bioscience, Inc
9.8 Quidel Corporation
9.9 Sekisui Diagnostics
9.10 Thermo Fisher Scientific Inc
9.11 List Not Exhaustive
10. Future Market Outlook